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STRENGTHS AND LIMITATIONS OF
FUNCTIONAL HEALTH STATUS INSTRUMENTS
FOR OSTEOARTHRITIS
Kelleher JK1, Stephens JM2, Haider S3, Pashos CL1
1Abt Associates Clinical Trials, Cambridge, MA, USA; 2Abt
Associates Clinical Trials, Bethesda, MD, USA; 3Pﬁzer, Inc,
Groton, CT, USA
The number of people with arthritis in the US was 43
million in 1998, and is projected to reach 60 million by
2020. The burden of arthritis is substantial and is respon-
sible for $65 billion annually in direct medical costs and
lost productivity. The most common form of arthritis,
osteoarthritis (OA), currently affects over 20 million
adults in the US. Because OA has no known cure, the
goals of therapy are symptom relief and improvement in
patient-reported outcomes.
OBJECTIVES: Our objective was to systematically
review disease-speciﬁc functional health status instru-
ments recommended in consensus guidelines for clinical
research in OA (as established by Outcome Measures in
Rheumatoid Arthritis Clinical Trials (OMERACT) and
OsteoArthritis Research Society International (OARSI))
and to assess their ability to predict economic outcomes.
METHODS: Computerized literature searches were 
conducted in the following databases from 1978–2002:
EMBASE, HealthSTAR, MEDLINE, and PSYCHINFO.
Manual searches were also conducted. The six disease-
speciﬁc instruments recommended by the OMERACT/
OARSI guidelines were reviewed with regard to their
domains, psychometric properties, and usefulness in 
clinical research: the Health Assessment Questionnaire,
Arthritis Impact Measurement Scales, Western Ontario
and McMaster Universities Arthritis Index, Indices of
Clinical Severity, Australian/Canadian Osteoarthritis
Hand Index, and the Algofunctional Index.
RESULTS: Substantial variation in the psychometric
properties and domains covered by the instruments was
found. Physical function and pain were the domains
which were most frequently emphasized and which
seemed to have the most value in predicting economic
burden of disease. Underrepresented areas included the
mental, social and emotional aspects of OA.
CONCLUSIONS: Additional research should evaluate
the usefulness of various instruments in assessing the
impact of OA treatments through change in physical and
psychological health status over the long term. Further
evaluation of instruments’ predictability of economic out-
comes is needed.
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CALCIUM SUPPLEMENTATION AND
REDUCTION IN ASSOCIATED FRACTURES IN
MEDICAID OSTEOPOROSIS PATIENTS
Dodd MA, Shah BM, Gupchup GV,Anderson JR
The University of New Mexico, Albuquerque, NM, USA
OBJECTIVES: To increase calcium supplementation in
Medicaid patients diagnosed with or at high risk for
osteoporosis. To reduce the number of osteoporosis 
associated bone fractures. To determine if mailing to the
patient only or the patient and their health care provider
is more effective in changing calcium prescribing.
METHODS: New Mexico Medicaid fee-for-service
patients with prescription claims for osteoporosis or
chronic oral steroid therapy without prescription claims
for calcium supplementation from October 2000 through
February 2001 were identiﬁed. The state was divided into
four geographical regions. These regions were randomly
assigned to the following intervention groups: 1) patient
only, 2) patient and prescriber, 3) patient and community
pharmacy, 4) patient, prescriber, and community phar-
macy. The patients and their health care providers were
mailed osteoporosis and calcium educational materials
according to their group. The prescription claims data-
base was reviewed 3 months following the mailing for
new calcium prescription claims. Based on a previous 
epidemiologic study and Medicare reimbursement for 
hip fractures, a cost analysis was performed.
RESULTS: A total of 1,094 patients, 239 prescribers, and
108 community pharmacies were included in the inter-
vention. Three months following the mailing 10.6% (n =
109) of the remaining eligible patients had calcium 
prescription claims. Calcium prescription claims were
present for 6.9%, 8.4%, 10.2%, and 16.6% of the
patients in groups 1, 2, 3, and 4, respectively. Hip frac-
ture associated hospital costs of $10,780 will potentially
be saved by avoiding 1.33 hip fractures per year. Net
savings of $4357 will potentially be achieved.
CONCLUSIONS: Educational materials mailed to the
patient, prescriber, and community pharmacy resulted 
in the highest change in therapy. The addition of calcium
supplementation to osteoporosis patients’ drug therapy
can potentially result in signiﬁcant cost savings and avoid
hospitalizations.
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UTILIZATION CHARACTERISTICS OF COX-2
INHIBITORS IN A LARGE MANAGED CARE
HEALTH PLAN
Yu W1, Kiang G1, Etemad LR2
1WellPoint Pharmacy Management, West Hills, CA, USA;
2University of Southern California, Los Angeles, CA, USA
OBJECTIVES: Prevalence of COX-2 inhibitor (celecoxib
and rofecoxib) use, with or without concurrent proton
pump inhibitor (PPI) therapy, and rate of therapy switch
were determined.
METHODS: Utilizing a pharmacy claim database from a
managed care health plan of over 1.9 million commercial
members, patients who had at least one paid claim for 
a COX-2 inhibitor during the year 2000 were identiﬁed.
Rate of therapy switch was calculated as the frequency of
change in COX-2 medication during the study period.
Previous PPI users were deﬁned as patients with a PPI
claim during the 45 days prior to the initial COX-2 paid
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claim. Patients were then followed for 30 and 60 days
post initiation of COX-2 therapy to evaluate rate of 
concurrent PPI use.
RESULTS: During 2000, 19,318 COX-2 users were iden-
tiﬁed (1.0% of total membership). Average (median)
number of COX-2 prescriptions ﬁlled was 3.4 (2) pre-
scriptions per COX-2 patient per year (pppy). Average
(median) quantity consumed pppy was 151 (80) capsules
for celecoxib and 91 (60) tablets for rofecoxib. Average
(median) length of therapy was 148 (86) days pppy.
During the study period, 16.7% of patients switched from
celecoxib to rofecoxib and 11.9% switched from rofe-
coxib to celecoxib. Of the 966 previous PPI users identi-
ﬁed, 62.3% and 56.8% continued on PPI therapy at 
30 and 60 days, respectively, post initiation of COX-2
therapy.
CONCLUSIONS: Length of COX-2 therapy for this pop-
ulation was relatively short and the majority of patients
who were utilizing a PPI prior to a COX-2 inhibitor con-
tinued on PPI therapy.
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TRENDS OF ANTIRESORPTIVE THERAPIES USE
AMONG WOMEN WITH PREVIOUS
OSTEOPOROTIC FRACTURE
Perreault S1, Desgagné A1, Boucher JM1, Blais L2, Le Lorier J1,
Ste-Marie LG3
1Montreal University, Montreal, QC, Canada; 2Montreal
University, Montreal, QC, Canada; 3University of Montreal,
Montreal, QC, Canada
Evidence for the efﬁcacy of antiresorptive therapies
(ART) is convincing for the most part in terms of risk
reduction of osteoporotic fractures among high-risk
postmenopausal women. Very little information has been
published on the frequency of use of ART.
OBJECTIVE: To evaluate the probability (P) over time of
ART use in women aged 70 years and older who had 
at least one diagnosed osteoporotic fracture to those
without a fracture.
METHODS: A cohort design was used, and a random
sample of women was collected from RAMQ database.
Women were classiﬁed in four cohorts, of which two
status were deﬁned: those with a fracture and those
without fracture in the 5 years prior to cohort entry. The
cohort entry was deﬁned as January 95, 96, 98 and 2000.
These women were followed up for a year after cohort
entry. Several exclusion criteria applied in the 5 years
prior cohort entry were used. We stopped to follow
women at their 85th birth date. The P of ﬁlling at least
one prescription of ART during the year following cohort
entry was determined using a logistic regression adjusting
for age.
RESULTS: Mean age and CDS were 78 years old and 3.3.
Prior use of ART ranged from 8.9% to 31.2%, and 8.7%
to 17.2 for women with and without fracture, respec-
tively. The P of ﬁlling at least one prescription of ART
excluding HRT from 1995 to 2001 ranged from 1.6% to
28.3% and from 0.5% to 11.3% among women with and
without fracture, respectively. The P of ﬁlling at least one
prescription of HRT ranged from 7.2% to 9.3% for
women with and without fracture.
CONCLUSION: Our results show an increase of ART
use excluding HRT overtime. But, there is still an under-
use of ART among women with fracture.
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MISSED OPPORTUNITIES IN
PHARMACEUTICAL TREATMENT OF
OSTEOPOROSIS IN POST-FRACTURE WOMEN
Wall MJ1, Beilfuss CD1, Graff JS1, McBurney CR1,
Fendrick AM2
1University of Michigan and Pﬁzer Inc, Ann Arbor, MI, USA;
2University of Michigan, Ann Arbor, MI, USA
OBJECTIVE: An estimated 9.4 million people in the
United States have osteoporosis. The prevalence of verte-
bral fractures is estimated at between 10% and 25% in
women aged 50 and over, with recent longitudinal studies
stating that bone loss accelerates with age. The risk for a
fracture is highly predictable by an initial fracture (OR =
2.1), leading to great opportunity for prevention of 
secondary fracture with pharmacotherapy. The purpose
of this study is to assess the prevalence of failing to treat
women, post-fracture, with pharmaceuticals.
METHODS: This is a retrospective database review of 
a Southeastern Michigan managed care organization’s
medical claims data from January 1, 1996, and pharmacy
claims data from January 1, 1997, through March 21,
2001. Data include women > 45 years of age before
January 1, 2001, with diagnosis of non-traumatic frac-
ture via CPT and ICD-9 codes. Treatment is deﬁned with
pharmacy claims data of estrogens, bisphosphonates,
raloxifene, or salmon calcitonin.
RESULTS: We identiﬁed 188 women (mean age at event
= 68.0 years) with fracture eligible for treatment, 89
(47%) did not receive treatment before fracture, and 74
(39%) following fracture. The decrease from 89 patients
pre-fracture to 74 patients post-fracture failing to receive
treatment is the net effect of 6 patients stopping treatment
and 21 patients beginning treatment.
CONCLUSIONS: The occurrence of a fracture represents
an opportunity to prevent further osteoporotic fractures.
There is an opportunity to increase patient outcomes to
prevent secondary fracture in women 45 years and older.
More than one-third of potentially eligible women were
not being treated with available medications.
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REFILL ADHERENCE IN OSTEOPOROTIC
WOMEN WITH PRIMARY AND SECONDARY
FRACTURE PREVENTION
Beilfuss CD1,Wall MJ1, Graff JS1, McBurney CR1,
Fendrick AM2
1University of Michigan and Pﬁzer Inc, Ann Arbor, MI, USA;
2University of Michigan, Ann Arbor, MI, USA
OBJECTIVE: The US national cost of osteoporosis was
estimated at $6.1 billion in 1984 and $20 billion in 1998.
